1. Trends & External Forces

Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress

Written by Posted on Less than 0 min read

Summer unofficially began over the weekend. To mark the occasion, here are a few hot items, freshly seared on the Drug Channels grill:

Plus: A special moment for DCI on Capitol Hill.

P.S. Join my 63,000+ LinkedIn followers for daily links to neat stuff, along with sharp and thoughtful commentary from the DCI community.

What’s Next for Retail Pharmacy: Data, Debate, and Disruption.

Don’t miss DCI’s June 20, 2025, webinar, featuring Dr. Adam J. Fein and Antonio Ciaccia. We’ll unpack the good, the bad, and the ugly of the pharmacy industry—and explore what it means for you. This dynamic session will blend expert insights and real-time debate. Join us!

Read more »

© 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Post Views: 62
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

How Field Reimbursement Services Help Overcome Coverage Barriers and Improve Patient Outcomes

Today’s guest post comes from Kimberley Chiang, Vice President of Biopharma Commercial Solutions at CoverMyMeds Kimberley highlghts the crucial roles of field reimbursement managers in removing access and reimbursement barriers. She then identifies the keys to successful implementation of field reimbursement services. To learn more, register for CoverMyMeds’ November 13, 2024, webinar: Specialty Therapies & […]
2 min read
0
  1. Media & Marketing

Gross-to-Net Bubble Hits $356B in 2024—But Growth Slows to 10-Year Low

Is the gross-to-net bubble—the ever-widening gap between brand-name drug sales at list prices and their net revenues after rebates and discounts—finally beginning to deflate? Drug Channels Institute (DCI) estimates that the gross-to-net reductions for all brand-name drugs reached $356 billion in 2024, a 7% increase over the previous year. Yet despite this record total, the […]
2 min read
0
  1. Department: HBC

NOW AVAILABLE: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

I am pleased to announce that Drug Channels Institute’s new 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers is now available for purchase and immediate download. Download a free 30-page report overview—including key industry trends, What’s New in this edition, the Table of Contents, and a List of Exhibits Read the press release: […]
4 min read
0
  1. Department: HBC

Hospitals Are Relying More on PBMs to Manage Manufacturers’ 340B Contract Pharmacy Restrictions: DCI’s 2024 Market Analysis (rerun)

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post from June 2024. The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market […]
3 min read
0
  1. Channel: Drug

Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies

Two weeks ago, Senator Bill Cassidy—now chair of the Senate Committee on Health, Education, Labor, and Pensions (HELP)—dropped a must-read, eyebrow-raising report on the out-of-control 340B Drug Pricing Program. (Link below.) The report reveals previously confidential information showing how billions are funneled to health systems and pharmacies—with manufacturers unable to follow the flow. Below, we […]
2 min read
0
  1. Data & Insights

Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation

Today’s guest post comes from Aaron Crittenden, President of Rx Marketplace at GoodRx. Aaron introduces us to GoodRx Community Link, a new offering from GoodRx that allows independent pharmacies to contract directly with GoodRx.  To learn about GoodRx Community Link, register for GoodRx’s free webinar on either June 3, 2025, or June 4, 2025. Both […]
2 min read
0
  1. Data & Insights

NOW AVAILABLE: The 2025–26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce Drug Channels Institute’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download. Download a free 25-page report overview—including key industry trends, “What’s New,” Table of Contents, and List of Exhibits Review pricing/license options and download the full 2025-26 report Special launch pricing is […]
3 min read
0
  1. Data & Insights

Unlocking the Gate: The Critical First 24 Hours of Patient Hub Engagement

Today’s guest post comes from Kristine McGaughey, Vice President, Implementation at ConnectiveRx and Sam Blake, SVP, Hub Product at ConnectiveRx. Sam and Kristine discuss the importance of the first 24 hours of a patient’s engagement with a hub services program. They outline five reasons why two components—patient enrollment and successful benefits verification—dictate the effectiveness of […]
2 min read
0
  1. Holiday & Events

Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments

Eeek! It’s time for Drug Channels’ Halloween roundup of terrifying tales to share with your ghoulish fiends. This month’s tricks and treats: Spooky! Blue Shield of California frightens away the gross-to-net bubble with its Humira biosimilar strategy Vampiric! Prior authorization sinks its fangs into providers’ time Wicked! How the IRA will put a stake through […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, January 2025: Mark Cuban Fixes Healthcare, Payers’ G2N Bubble, Pharmacists Rejoice, 340B Shenanigans, and 46Brooklyn vs. Mushrooms

Get ready to climb a Crisco-covered light pole! DCI’s hometown Philadelphia Eagles are going to Super Bowl LIX! Go E-L-G-S-E-S! (No, that’s not a typo.) Before you overturn any cars, please enjoy this month’s playbook of articles, intercepted for you from the Drug Channels gridiron: Touchdown! How Mark Cuban would quarterback the U.S. healthcare system  […]
2 min read
0
  1. Trends & External Forces

The Future of Buy-and-Bill Market Access: Five Drivers of Wholesalers’ Vertical Integration with Physician Practices

Vertical integration continues to reshape U.S. healthcare, as detailed in DCI’s new 2025-26 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Our latest analysis shows how the Big Three companies—Cencora, Cardinal Health, and McKesson—are extending their reach far beyond drug distribution, building influence throughout the drug channel. In recent years, these companies have spent more […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, July 2025: 340B vs. Patients, Humira Whiplash, Accumulator Fallout, and Pharmacy Struggles

Let’s cut through the steamy summer haze with a refreshing breeze of industry insights from Drug Channels—perfect for pondering while you float in your favorite pool: 340B Discounts Still Not Reaching Needy Patients Why do patients switch from biosimilars back to Humira? Copay accumulator programs strike again! The Grim Outlook for Retail Pharmacies Plus, a […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2026 Video Webinar Series

Join Dr. Adam J. Fein, president of Drug Channels Institute (DCI), for three new video webinars during 2026. These live, interactive events are designed for executives who need timely insight into the rapidly changing U.S. drug channel. They will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. Register Now […]
4 min read
0
  1. Corporate Strategy

Addressing Gaps in Access: Strategies to Optimize Your Prescription Journey

Today’s guest post comes from Catherine Wood Hill, SVP of Marketing at PHIL. Catherine reviews the prescription lifecycle from the perspectives of patients, providers, and manufacturers. She explains how manufacturers can support patients with clear comunication about their prescriptions. Catherine then outlines five strategies to help providers have more informed conversations with patients. To learn […]
2 min read
0
  1. Shopper & Customer

Why the Pharmacy Supply Chain Is Broken and How SmithRx Is Fixing It

Today’s guest post comes from Jim Sheninger, Senior Vice President, Supply Chain at SmithRx. Jim reviews the evolution of pharmacy benefit managers (PBMs) within the drug channel and discusses the challenges that the industry’s current dynamics create for plan sponsors, patients, and pharmacies. He then outlines SmithRx’s approach to addressing these issues. To learn more, […]
2 min read
0
  1. Data & Insights

Unlocking AI’s Promise in Patient Support Programs

Today’s guest post comes from Chris Apolito, Chief Strategy Officer, and Karina Castagna, Senior Vice President, Commercial Strategy at Mercalis. Chris and Karina describe four ways that artificial intelligence (AI) can improve patient access, affordability, and adherence. To learn more, join Mercalis for a complimentary webinar on March 13, 2025: Modernizing Patient Support: Harnessing Advanced […]
2 min read
0
  1. Operations & Supply Chain

Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond

As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. During this period of volatility, the core business model of the Big Three public pharmaceutical distribution companies—Cardinal Health, Cencora, and McKesson—remains intact. Put simply: […]
2 min read
0
  1. Department: Food

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble Optum Rx joins the private label biosimilar bandwagon Biosimilars boom for provider-administered drugs Fresh evidence of how copay accumulators hurt patients […]
2 min read
0
  1. Data & Insights

Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025

Abracadabra! Small pharmacies have ghosted Medicare Part D’s preferred networks—no farewell party, no breakup text, just a quiet exit. A few months ago , DCI highlighted how the largest pharmacy chains are participating as preferred cost sharing pharmacies in the 2025 stand-alone prescription drug plan (PDP) networks. Today, we update our exclusive analysis of how […]
2 min read
0
  1. Corporate Strategy

The $90 Billion Leakage Problem: How RIS Rx Helps Pharma Recover Lost Revenue

Today’s guest post comes from Gerard Rivera, CEO and Co-Founder of RIS Rx. Gerard explores how pharma companies lose billions each year through copay program inefficiencies, accumulators, maximizers, and other forms of systemic leakage. He introduces RIS Rx, a healthcare technology company whose platform helps manufacturers mitigate gross-to-net (GTN) revenue leakage while supporting patient access […]
2 min read
0
Next